US Stock Market Indices Close Lower on Monday, August 11

Stock indices closed lower on Monday, with the Dow Jones 30 Industrials falling 0.454%, the Nasdaq Composite dropping 0.301%, and the S&P500 declining 0.250%. The Dow Jones 15 Utilities and Dow Jones 20 Transportation indices also declined. The Nikkei in Tokyo rose 1.854%.

Stock indices closed lower on Monday, reflecting investor concerns over President Donald Trump's tariffs. The Dow Jones 30 Industrials fell 0.454%, the Nasdaq Composite dropped 0.301%, and the S&P500 declined 0.250%. The Dow Jones 15 Utilities and Dow Jones 20 Transportation indices also experienced declines. Notably, the Nikkei in Tokyo rose 1.854%.

The U.S. stock market indexes, including the S&P 500, Dow Jones, and Nasdaq, slipped Tuesday following a weaker-than-expected report on activity for U.S. businesses in the transportation, retail, and other services industries. This report added to worries that President Trump's tariffs may be hurting the economy [3]. However, hopes for coming cuts to interest rates by the Federal Reserve and a stream of stronger-than-expected profit reports from U.S. companies helped to keep losses in check.

Several companies reported significant declines in their stock prices due to tariffs. Edgewell Personal Care, for instance, fell 20.2% after reporting lower profit and revenue for the latest quarter than analysts expected. CEO Rod Little attributed the poor performance to a weak season for sun care in North America and the impact of tariffs on profits [3]. Similarly, Caterpillar slipped 0.7% after reporting a profit that fell short of analysts' expectations, largely due to tariffs making its manufacturing costs more expensive [3].

The Dow Jones Industrial Average (DJIA) also saw significant changes recently. In August 2020, Amgen (AMGN) joined the DJIA, replacing Pfizer. This move was prompted by Apple's 4:1 stock split and a desire to diversify the index [2]. Amgen's inclusion reflects the rising importance of biotech in the American economy. Since joining the DJIA, Amgen's stock has seen significant growth, with the stock price increasing by almost 50% [2].

Despite these declines, the market remains cautiously optimistic. Analysts are cautiously bullish on Amgen, with the average 12-month price target at $319.33 and a forecast increase over the next year of 10.76% [2]. Firms like Morgan Stanley and UBS expect a 15-25% upside if Amgen's new drugs and biosimilars perform well [2]. However, much rides on execution, as any big R&D setbacks could temper expectations.

References:
[1] https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nvidia-stock-amd-ai-chip/
[2] https://www.disruptionbanking.com/2025/08/11/amgen-dow-jones-biosimilars-tepezza-2025/
[3] https://economictimes.indiatimes.com/news/international/us/us-stock-market-today-palantir-technologies-axon-enterprise-yum-brands-stocks-jump-but-sp-500-dow-jones-nasdaq-are-down/articleshow/123122872.cms?UTM_Campaign=RSS_Feed&UTM_Medium=Referral&UTM_Source=Google_Newsstand&from=mdr